Biosimilar filgrastim is a type of medication that is produced to be highly similar to the reference product, filgrastim, but at a lower cost. Filgrastim is a recombinant human granulocyte-colony stimulating factor (G-CSF) that is used to support the production of white blood cells in patients undergoing chemotherapy or bone marrow transplantation. Biosimilar filgrastim is developed through a complex process known as biologic manufacturing, which involves using living organisms to produce the medication. The goal of biosimilar filgrastim is to provide a more affordable alternative to the reference product while maintaining comparable effectiveness and safety. Research in this area focuses on evaluating the pharmacokinetics, pharmacodynamics, clinical efficacy, immunogenicity, and safety of biosimilar filgrastim compared to the reference product. This research is essential to ensure that biosimilar filgrastim meets regulatory standards and can be approved for use in clinical practice.